EQRX News and Press, EQRx Inc. From 11/10/22

Aumolertinib: Clarity on path for potential U.S. approval; continue to pursue ex-U.S. approvals based on existing data, with MAA under review by U.K.’s MHRA Sugemalimab: Based on recent FDA feedback, EQRx has concluded that there is no commercially viable path for sugemalimab p...

CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at substantially lower prices, today announced that management will participate in a fireside chat ...

CAMBRIDGE, Mass., Oct. 28, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at substantially lower prices, today announced it will host a conference call and webcast on Thursd...

Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports and conference presentat...

Summary CKPT produced strong data for cosibelimab. However, data was ex-US and from an open-label trial. There's not much cash at CKPT. Checkpoint Therapeutics ( CKPT ) produced positive results from the registration trial of cosibelimab in skin cancer, however t...

Summary EQRx's goal is to make drugs affordable; its strategy - get those drugs cheap from China. I don't see an innovation here, and that bothers me. The company has huge cash, which is a positive. EQRx ( EQRX ) is a late-stage developer of medicines for oncolog...

EQRx, Inc. (EQRX) Q2 2022 Earnings Conference Call August 11, 2022, 08:00 AM ET Company Participants Neil Swami - Head, IR Melanie Nallicheri - President and CEO Jami Rubin - CFO Eric Hedrick - Chief Physician Executive Conference Call Participants ...

EQRx press release ( NASDAQ: EQRX ): Q2 GAAP EPS of -$0.17 beats by $0.03 . Cash, cash equivalents and short-term investments totaled $1.6 billion at June 30, 2022. EQRx expects to maintain sufficient capital resources to fund anticipated operations at least into 2...

Initiated a U.S.-led, comparative Phase 3b clinical trial with aumolertinib for the first-line treatment of EGFR-mutated NSCLC Announced U.K. MHRA acceptance of EQRx’s first regulatory submission (aumolertinib) for review; first sugemalimab regulatory submission expected ex-U.S...

In the ongoing GEMSTONE-301 Phase 3 study, sugemalimab, administered after treatment with either concurrent or sequential chemoradiotherapy, demonstrated a statistically significant improvement in progression-free survival versus placebo in patients with unresectable Stage III non-small c...